China accepted the drug registration application of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) units Yaopharma and Jisimei (Wuhan) Pharmaceutical for their injectables, according to a Monday filing with the Hong Kong Exchange.
Yaopharma is the manufacturer of levofloxacin injection for mild, moderate, and severe bacterial infections such as hospital and community-acquired pneumonia, and other infections, the filing said.
Jisimei (Wuhan) Pharmaceutical manufactures cytarabine injection for acute myelogenous leukemia and other types of leukemia, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。